SyneuRx is pioneering and developing revolutionary, completely new classes of drug to answer the unmet medical needs in central nervous system (CNS) disorders. Our candidate drugs hold great promise to fast track the development process and reach a dominant position in the CNS drug market quickly. The candidates in our pipeline represent a rare opportunity with low risk and potential success.
SyneuRx was founded in 2013 by several Taiwanese/Americans with the goal to realize the scientific breakthroughs to develop novel CNS drugs for mental/behavior health. Our multi-national team is located in both the US and Greater China regions. The innovations, resources and production from both US and Asia are the strength of our team. The experienced team has developed and tested multiple candidate drugs in human with unexpected good efficacy and negligible side effects. They bring exceptional technical expertise and business experience to the enterprise to promise the success of launching new drugs in relatively short period of time.